KOLOA, Hawaii — Faricimab helped improve vision in previously untreated patients with neovascular age-related macular degeneration, according to a real-world study presented at Retina 2025.
Ferhina S. Ali, MD, MPH, presented an update on clinical outcomes from FARETINA-AMD, a retrospective real-world study that used data from the IRIS Registry.
The study included patients with a diagnosis of neovascular AMD who received at least one faricimab injection between February 2022 and March 2023. All patients had at least 12 months of medical data before starting faricimab and at least 12 months